GSK Aug 2024 47.000 call
| Previous Close | 0.6000 |
| Open | 0.6500 |
| Bid | 0.6500 |
| Ask | 0.7500 |
| Strike | 47.00 |
| Expire Date | 2024-08-16 |
| Day's Range | 0.6000 - 0.6500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 334 |
BloombergModerna's New RSV Vaccine Undercuts the Promise of mRNA
(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t Track‘Seriously Underwater’ Home Mortgages Tick Up Across th
Simply Wall St.GSK (LON:GSK) Is Paying Out A Dividend Of £0.15
GSK plc's ( LON:GSK ) investors are due to receive a payment of £0.15 per share on 11th of July. The dividend yield...
GlobeNewswireBioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections
